Navigating adalimumab biosimilars: an expert opinion
The patent expiry of Humira in 2018 opened up the current European market to eight adalimumab biosimilars - (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio, Imraldi and Yuflyma - for the treatment of various immune and inflammatory conditions. Amjevita, Hadlima, Hyrimoz...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Becaris Publishing Limited,
2023-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!